Herophilus Heroes
System1 Biosciences is now Herophilus. The rebrand reflects the progression of our company from platform technology development to therapeutics development using the platform we’ve built.
What’s the meaning behind the new name? Herophilus was an Alexandrian physician (circa 300 BC) who pioneered the use of what we now call biophenotyping — he was the first to study the tissue and organs of cadavers to understand the etiology of disease, an out-of-the-box view at the time. Herophilus was arguably the first neuroscientist: he was the first to prove that the brain, not the heart, was the seat of the intellect, revising the predominant view that held for two millennia since ancient Egypt. He was also the first to identify that nerves were distinct from blood vessels and tendons. We think of Herophilus as the philosophical forebearer of our company’s approach. (To pronounce Herophilus, stress the second syllable using a short ‘o’ — HeRAHphilus.)
We’re a talented group of scientists and technologists taking an out-of-the-box view to understand the etiology of brain disease and brought together by a mission that matters: to cure brain disorders using humanity’s best science.

Scientific Advisory Board

Alex Pollen, PhD
UCSF
Organoids & Brain Development

Bjoern Schwer, MD, PhD
UCSF
Stem Cells & Brain Development

Elizabeth Hillman, PhD
Columbia University
Microscopy & Neuroscience

Jeffrey Lieberman, MD
Columbia University
Psychiatry

Jennifer Garrison, PhD
Buck Institute
Neuroscience

Joseph Gogos, MD, PhD
Columbia University
Cellular Biophysics & Neuroscience

Larry Abbott, PhD
Columbia University
Computational Neuroscience

Paola Arlotta, PhD
Harvard University
Organoids & Brain Development

Scott Linderman, PhD
Stanford University
Neuroscience & Machine Learning

Surya Ganguli, PhD
Stanford University
Neuroscience & Machine Learning